Truxima Becomes First Biosimilar to Rituxan Approved in US for Non-Hodgkin’s Lymphoma
News
The U.S. Food and Drug Administration has approved Truxima (rituximab-abbs), a biosimilar to Rituxan (rituximab), for three CD20-positive non-Hodgkin’s lymphoma indications, Celltrion and Teva announced. The decision comes less than two months after the FDA’s Oncologic Drugs ... Read more